During the last session, Emergent Biosolutions Inc (NYSE:EBS)’s traded shares were 9.84 million, with the beta value of the company hitting 1.62. At the end of the trading day, the stock’s price was $8.31, reflecting an intraday loss of -6.73% or -$0.6. The 52-week high for the EBS share is $15.10, that puts it down -81.71 from that peak though still a striking 82.91% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $439.68M, and the average intraday trading volume over the past 10 days was 4.61 million shares, and the average trade volume was 3.10 million shares over the past three months.
Emergent Biosolutions Inc (EBS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. EBS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Emergent Biosolutions Inc (NYSE:EBS) trade information
Emergent Biosolutions Inc (EBS) registered a -6.73% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.73% in intraday trading to $8.31, hitting a weekly high. The stock’s 5-day price performance is -12.80%, and it has moved by -21.38% in 30 days. Based on these gigs, the overall price performance for the year is 83.04%. The short interest in Emergent Biosolutions Inc (NYSE:EBS) is 3.46 million shares and it means that shorts have 1.11 day(s) to cover.
The consensus price target of analysts on Wall Street is $51.5, which implies an increase of 83.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $38 and $65 respectively. As a result, EBS is trading at a discount of -682.19% off the target high and -357.28% off the low.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Statistics show that Emergent Biosolutions Inc has outperformed its competitors in share price, compared to the industry in which it operates. Emergent Biosolutions Inc (EBS) shares have gone up 145.13% during the last six months, with a year-to-date growth rate more than the industry average at 68.22% against 18.00.
While earnings are projected to return 67.74% in 2024.
EBS Dividends
Emergent Biosolutions Inc is due to release its next quarterly earnings on 2024-Nov-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Emergent Biosolutions Inc insiders own 2.18% of total outstanding shares while institutional holders control 58.99%, with the float percentage being 60.30%. BLACKROCK INC. is the largest shareholder of the company, while 174.0 institutions own stock in it. As of 2024-06-30, the company held over 3.84 million shares (or 7.3551% of all shares), a total value of $26.18 million in shares.
The next largest institutional holding, with 3.67 million shares, is of VANGUARD GROUP INC’s that is approximately 7.0234% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $25.0 million.
